MannKind Corp. (MNKD) Approved for Inhaled Insulin Treatment

Shares of MannKind Corporation (MNKD) were trading up +1.90 or +19.00 percent to $11.90 per share in pre-market trading Monday morning. Mannkind announced over the weekend that the company had finally gained approval for its inhaled insulin drug AFREZZA from the U.S. Food and Drug Administration or FDA. Mannkind shares closed at $10.00 per share, down -0.58 or -5.48 percent in Fridayâ s regular trading session.

Stock Analysis Founded in 1991, Valencia, California based Mannkind Corporation is a biopharmaceutical company involved in developing and commercializing therapeutic products for the treatment of diabetes and other diseases. The companyâ s main product, AFREZZA, is a powdered substance used in the treatment of diabetes. Mannkindâ s base for clinical research and development, as well as commercial operations and regulatory issues is based in Paramus, New Jersey, while their manufacturing facility is located in Danbury, Connecticut. AFREZZA uses Mannkindâ s proprietary â

Published on Jun 30, 2014
By Jay Hawk
Jay Hawk
Jay Hawk enjoyed a 12-year professional financial markets career incorporating extensive first hand futures and options experience obtained by trading in the stock, commodity and forex markets on U.S. exchanges. Since retiring as a full-time financial market professional, he has been actively trading stock, commodities, forex and options for his own account and managing funds for others, as well as writing financial market commentary and educational articles.

Copyrighted 2020. Content published with author's permission.

Posted in ...